Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer

• Published in: British journal of radiology Vol. 88; no. 1048; p. 20140800
• Main Authors: Pernin, V, Belin, L, Cottu, P, Bontemps, P, Lemanski, C, De La Lande, B, Baumann, P, Missohou, F, Levy, C, Peignaux, K, Reynaud-Bougnoux, A, Denis, F, Gobillion, A, Bollet, M, Vago, N A, Dendale, R, Campana, F, Fourquet, A, Kirova, Y M
• Format: Journal Article
• Language: English
• Published: England The British Institute of Radiology 01.04.2015
• Subjects: Adult; Angiogenesis Inhibitors - adverse effects; Antibodies, Monoclonal, Humanized - adverse effects; Bevacizumab; Breast; Breast Neoplasms - drug therapy; Breast Neoplasms - radiotherapy; Breast Neoplasms - surgery; Chemotherapy, Adjuvant - adverse effects; Female; France; Humans; Interventional and Vascular; Lymphatic Metastasis - radiotherapy; Mastectomy; Middle Aged; Neuroradiology; Radiotherapy, Adjuvant - adverse effects; Treatment Outcome; France
• ISSN: 0007-1285; 1748-880X
• DOI: 10.1259/bjr.20140800

To evaluate the safety of the concurrent combination of bevacizumab with adjuvant radiotherapy (B-RT) in breast cancer (BC). Multicentre, prospective study, of the toxicity of adjuvant radiotherapy (RT) alone or B-RT in patients with non-metastatic BC enrolled in randomized Phase 3 BEATRICE trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during and 12 months after the completion of RT. From 2007 to 2012, 39 females received adjuvant B-RT and 45 received adjuvant RT alone. Median follow-up was 21.5 months. All patients had triple-negative non-metastatic BC and received adjuvant chemotherapy followed by RT. 90% of the 39 females treated by concurrent B-RT received whole breast irradiation (WBI) with a boost and 4 (10%) received post-mastectomy RT. Lymph node RT was delivered in 49% of the females with internal mammary chain irradiation. The mean duration of bevacizumab was 11.7 months. 38 (84%) females treated by RT alone received WBI with a boost and 16% of the females received post-mastectomy RT. Lymph node RT was delivered in 47% of the females with internal mammary chain RT in 31%. Grade 3 acute dermatitis was observed in 9% of patients receiving B-RT and 5% of patients receiving RT alone with no significant difference. 1 year after the completion of RT, the most common late grade 1-2 toxicities in the B-RT group were pain (18%), fibrosis (8%) and telangiectasia (5%). The concurrent bevacizumab with locoregional RT is associated with acceptable early and late 1-year toxicities in patients with BC. The largest series of this association.